

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Erik Buntinx  
Serial No. : 10/725,965  
Filed : December 2, 2003  
For : METHOD OF TREATING MENTAL DISORDERS USING OF D4  
AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR  
PARTIAL AGONISTS  
Art Unit : 1617  
Examiner : Umamaheswari Ramachandran  
Customer No. : 1912  
Confirmation No.: 2844

**COMMUNICATION IN REPLY TO JUNE 8, 2010 AND JUNE 9, 2010**  
**INTERVIEW SUMMARIES**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Communication is submitted in reply to the Interview Summaries mailed on June 8 and June 9, 2010 in connection with U.S. Patent Application Nos. 10/752,423 and 10/725,965.

Applicant's undersigned attorney thanks Examiner Umamaheswari Ramachandran for the courtesy of telephonic interviews on May 25 and May 27, 2010, and concurs with the Examiner's Interview Summaries dated June 8, 2010 and June 9, 2010.

EFS

Confirmation No. 2844

Applicant: Erik Buntinx

Serial No.: 10/725,965

Filed: December 2, 2003

July 2, 2010 Communication in Reply to Interview Summaries

page 2 of 2

No fee is deemed necessary in connection with the submission of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: July 2, 2010  
New York, New York

By /Alan D. Miller/  
Alan D. Miller, Reg. No. 42,889